Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity

Journal of Biological Chemistry

Volumn 289, Issue 10, 2014, Pages 6551-6564

  David, Marion ^a   Machuca Gayet, Irma ^b   Kikuta, Junichi ^c,d   Ottewell, Penelope ^e   Mima, Fuka ^c,d   Leblanc, Raphael ^a   Bonnelye, Edith ^a   Ribeiro, Johnny ^a   Holen, Ingunn ^e   Vales, Rùben Lopez ^f   Jurdic, Pierre ^b   Chun, Jerold ^g   Clézardin, Philippe ^a   Ishii, Masaru ^c,d   Peyruchaud, Olivier ^a  

^a INSERM   (France)

^b Univ Lyon 1   (France)

^c OSAKA UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; PHOSPHOLIPIDS;

BIOACTIVE LIPIDS; BONE HOMEOSTASIS; BONE RESORPTION; DEGRADATION ACTIVITY; LYSOPHOSPHATIDIC ACID; OSTEOCLAST DIFFERENTIATION; PHARMACOLOGICAL BLOCKADE; THERAPEUTIC TARGETS;

BONE;

BISPHOSPHONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CX3CR1; DEBIO 0719; ENHANCED GREEN FLUORESCENT PROTEIN; KIL 6425; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR TYPE 1; LYSOPHOSPHATIDIC ACID RECEPTOR TYPE 1 ANTAGONIST; MEMBRANE PROTEIN; NUCLEAR FACTOR OF ACTIVATED T CELL CYTOPLASMIC 1; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VPC 12249;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; CELL FUSION; CELL MATURATION; CELL MOTILITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE DELETION; KNOCKOUT MOUSE; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OVARIECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRABECULAR BONE; UPREGULATION; WILD TYPE;

BONE; DIFFERENTIATION; LYSOPHOSPHOLIPID; OSTEOCLAST; OSTEOPOROSIS; RECEPTORS;

ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CELL MOVEMENT; FEMALE; ISOXAZOLES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NFATC TRANSCRIPTION FACTORS; OLEIC ACIDS; ORGANOPHOSPHATES; OSTEOCLASTS; PROPIONATES; RECEPTORS, LYSOPHOSPHATIDIC ACID;

EID: 84896748731     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.533232     Document Type: Article

References (75)

1. Rodan, G. A., and Martin, T. J. (2000) Therapeutic approaches to bone diseases. Science 289, 1508-1514
2. Jacobs, C. R., Temiyasathit, S., and Castillo, A. B. (2010) Osteocyte mechanobiology and pericellular mechanics. Annu. Rev. Biomed. Eng. 12, 369-400
3. Nakashima, T., Hayashi, M., and Takayanagi, H. (2012) New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol. Metab. 23, 582-590
4. Takeda, S., and Karsenty, G. (2001) Central control of bone formation. J. Bone Miner. Metab. 19, 195-198
5. Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., Harada, Y., Azuma, Y., Krust, A., Yamamoto, Y., Nishina, H., Takeda, S., Takayanagi, H., Metzger, D., Kanno, J., Takaoka, K., Martin, T. J., Chambon, P., and Kato, S. (2007) Estrogen prevents bone loss via estrogen receptor and induction of Fas ligand in osteoclasts. Cell 130, 811-823
6. Houben, A. J., and Moolenaar, W. H. (2011) Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 30, 557-565
7. Mansell, J. P., Nowghani, M., Pabbruwe, M., Paterson, I. C., Smith, A. J., and Blom, A. W. (2011) Lysophosphatidic acid and calcitriol co-operate to promote human osteoblastogenesis: requirement of albumin-bound LPA. Prostaglandins Other Lipid Mediat. 95, 45-52
8. Lapierre, D. M., Tanabe, N., Pereverzev, A., Spencer, M., Shugg, R. P., Dixon, S. J., and Sims, S. M. (2010) Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival. J. Biol. Chem. 285, 25792-25801
9. Karagiosis, S. A., and Karin, N. J. (2007) Lysophosphatidic acid induces osteocyte dendrite outgrowth. Biochem. Biophys. Res. Commun. 357, 194-199
10. Moolenaar, W. H. (2000) Development of our current understanding of bioactive lysophospholipids. Ann. N.Y. Acad. Sci. 905, 1-10
11. Eichholtz, T., Jalink, K., Fahrenfort, I., and Moolenaar, W. H. (1993) The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291, 677-680
12. Boucharaba, A., Serre, C.-M., Grès, S., Saulnier-Blache, J. S., Bordet, J.-C., Guglielmi, J., Clézardin, P., and Peyruchaud, O. (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114, 1714-1725
13. Panupinthu, N., Rogers, J. T., Zhao, L., Solano-Flores, L. P., Possmayer, F., Sims, S. M., and Dixon, S. J. (2008) P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J. Cell Biol. 181, 859-871
14. Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T., Lin, M. E., Teo, S. T., Park, K. E., Mosley, A. N., and Chun, J. (2010) LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157-186
15. Mutoh, T., Rivera, R., and Chun, J. (2012) Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol. 165, 829-844
16. Noguchi, K., Herr, D., Mutoh, T., and Chun, J. (2009) Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 9, 15-23
17. Choi, K. U., Yun, J. S., Lee, I. H., Heo, S. C., Shin, S. H., Jeon, E. S., Choi, Y. J., Suh, D. S., Yoon, M. S., and Kim, J. H. (2010) Lysophosphatidic acidinduced expression of periostin in stromal cells: Prognostic relevance of periostin expression in epithelial ovarian cancer. Int. J. Cancer 128, 332-342
18. Sims, S. M., Panupinthu, N., Lapierre, D. M., Pereverzev, A., and Dixon, S. J. (2013) Lysophosphatidic acid: A potential mediator of osteoblastosteoclast signaling in bone. Biochim. Biophys. Acta 1831, 109-116
19. Contos, J. J., Fukushima, N., Weiner, J. A., Kaushal, D., and Chun, J. (2000) Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl. Acad. Sci. U.S.A. 97, 13384-13389
20. Hecht, J. H., Weiner, J. A., Post, S. R., and Chun, J. (1996) Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135, 1071-1083
21. Kingsbury, M. A., Rehen, S. K., Contos, J. J., Higgins, C. M., and Chun, J. (2003) Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat. Neurosci. 6, 1292-1299
22. Inoue, M., Rashid, M. H., Fujita, R., Contos, J. J., Chun, J., and Ueda, H. (2004) Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat. Med. 10, 712-718
23. Yung, Y. C., Mutoh, T., Lin, M. E., Noguchi, K., Rivera, R. R., Choi, J. W., Kingsbury, M. A., and Chun, J. (2011) Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci. Transl. Med. 3, 99ra87
24. Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., and Luster, A. D. (2008) The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14, 45-54
25. Lin, S., Yeruva, S., He, P., Singh, A. K., Zhang, H., Chen, M., Lamprecht, G., de Jonge, H. R., Tse, M., Donowitz, M., Hogema, B. M., Chun, J., Seidler, U., and Yun, C. C. (2010) Lysophosphatidic acid stimulates the intestinal brush border Na+/H exchanger 3 and fluid absorption via LPA(5) and NHERF2. Gastroenterology 138, 649-658
26. Panchatcharam, M., Miriyala, S., Yang, F., Rojas, M., End, C., Vallant, C., Dong, A., Lynch, K., Chun, J., Morris, A. J., and Smyth, S. S. (2008) Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 103, 662-670
27. Dusaulcy, R., Daviaud, D., Pradère, J. P., Grès, S., Valet, P., and Saulnier-Blache, J. S. (2009) Altered food consumption in mice lacking lysophosphatidic acid receptor-1. J. Physiol. Biochem. 65, 345-350
28. Gennero, I., Laurencin-Dalicieux, S., Conte-Auriol, F., Briand-Mésange, F., Laurencin, D., Rue, J., Beton, N., Malet, N., Mus, M., Tokumura, A., Bourin, P., Vico, L., Brunel, G., Oreffo, R. O., Chun, J., and Salles, J. P. (2011) Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone 49, 395-403
29. Contos, J. J., Ishii, I., Fukushima, N., Kingsbury, M. A., Ye, X., Kawamura, S., Brown, J. H., and Chun, J. (2002) Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell. Biol. 22, 6921-6929
30. Ye, X., Hama, K., Contos, J. J., Anliker, B., Inoue, A., Skinner, M. K., Suzuki, H., Amano, T., Kennedy, G., Arai, H., Aoki, J., and Chun, J. (2005) LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435, 104-108
31. Ye, X., Skinner, M. K., Kennedy, G., and Chun, J. (2008) Age-dependent loss of sperm production in mice via impaired lysophosphatidic acid signaling. Biol. Reprod. 79, 328-336
32. Sumida, H., Noguchi, K., Kihara, Y., Abe, M., Yanagida, K., Hamano, F., Sato, S., Tamaki, K., Morishita, Y., Kano, M. R., Iwata, C., Miyazono, K., Sakimura, K., Shimizu, T., and Ishii, S. (2010) LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood 116, 5060-5070
33. Liu, Y. B., Kharode, Y., Bodine, P. V., Yaworsky, P. J., Robinson, J. A., and Billiard, J. (2010) LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J. Cell. Biochem. 109, 794-800
34. Lin, M. E., Rivera, R. R., and Chun, J. (2012) Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain. J. Biol. Chem. 287, 17608-17617
35. An, S., Bleu, T., Hallmark, O. G., and Goetzl, E. J. (1998) Characterization of a novel subtype of humanGprotein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273, 7906-7910
36. Heise, C. E., Santos, W. L., Schreihofer, A. M., Heasley, B. H., Mukhin, Y. V., Macdonald, T. L., and Lynch, K. R. (2001) Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol. Pharmacol. 60, 1173-1180
37. Ohta, H., Sato, K., Murata, N., Damirin, A., Malchinkhuu, E., Kon, J., Kimura, T., Tobo, M., Yamazaki, Y., Watanabe, T., Yagi, M., Sato, M., Suzuki, R., Murooka, H., Sakai, T., Nishitoba, T., Im, D. S., Nochi, H., Tamoto, K., Tomura, H., and Okajima, F. (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64, 994-1005
38. David, M., Ribeiro, J., Descotes, F., Serre, C. M., Barbier, M., Murone, M., Clézardin, P., and Peyruchaud, O. (2012) Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int. J. Oncol. 40, 1133-1141
39. Lee, C. W., Rivera, R., Gardell, S., Dubin, A. E., and Chun, J. (2006) GPR92 as a new G12/13-and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281, 23589-23597
40. Yanagida, K., Masago, K., Nakanishi, H., Kihara, Y., Hamano, F., Tajima, Y., Taguchi, R., Shimizu, T., and Ishii, S. (2009) Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J. Biol. Chem. 284, 17731-17741
41. Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., and Littman, D. R. (2000) Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20, 4106-4114
42. Ishii, M., Egen, J. G., Klauschen, F., Meier-Schellersheim, M., Saeki, Y., Vacher, J., Proia, R. L., and Germain, R. N. (2009) Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458, 524-528
43. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101-1108
44. Teitelbaum, S. L., and Ross, F. P. (2003) Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638-649
45. Lattin, J., Zidar, D. A., Schroder, K., Kellie, S., Hume, D. A., and Sweet, M. J. (2007) G-protein-coupled receptor expression, function, and signaling in macrophages. J. Leukocyte Biol. 82, 16-32
46. Fueller, M., Wang, D. A., Tigyi, G., and Siess, W. (2003) Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. Cell. Signal. 15, 367-375
47. Duong, C. Q., Bared, S. M., Abu-Khader, A., Buechler, C., Schmitz, A., and Schmitz, G. (2004) Expression of the lysophospholipid receptor family and investigation of lysophospholipid-mediated responses in human macrophages. Biochim. Biophys. Acta 1682, 112-119
48. Jurdic, P., Saltel, F., Chabadel, A., and Destaing, O. (2006) Podosome and sealing zone: specificity of the osteoclast model. Eur. J. Cell Biol. 85, 195-202
49. Zhang, Q., Magnusson, M. K., and Mosher, D. F. (1997) Lysophosphatidic acid and microtubule-destabilizing agents stimulate fibronectin matrix assembly through Rho-dependent actin stress fiber formation and cell contraction. Mol. Biol. Cell 8, 1415-1425
50. Kalu, D. N. (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15, 175-191
51. Rissanen, J. P., Suominen, M. I., Peng, Z., and Halleen, J. M. (2008) Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif. Tissue Int. 82, 108-115
52. David, M., Wannecq, E., Descotes, F., Jansen, S., Deux, B., Ribeiro, J., Serre, C. M., Grès, S., Bendriss-Vermare, N., Bollen, M., Saez, S., Aoki, J., Saulnier-Blache, J. S., Clézardin, P., and Peyruchaud, O. (2010) Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE 5, e9741
53. McMichael, B. K., Meyer, S. M., and Lee, B. S. (2010) c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation. J. Biol. Chem. 285, 26641-26651
54. Ory, S., Brazier, H., Pawlak, G., and Blangy, A. (2008) Rho GTPases in osteoclasts: orchestrators of podosome arrangement. Eur. J. Cell Biol. 87, 469-477
55. Fukushima, N., Kimura, Y., and Chun, J. (1998) A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid. Proc. Natl. Acad. Sci. U.S.A. 95, 6151-6156
56. Moolenaar, W. H., Kranenburg, O., Postma, F. R., and Zondag, G. C. (1997) Lysophosphatidic acid: G-protein signalling and cellular responses. Curr. Opin. Cell Biol. 9, 168-173
57. Yu, S., Murph, M. M., Lu, Y., Liu, S., Hall, H. S., Liu, J., Stephens, C., Fang, X., and Mills, G. B. (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer Inst. 100, 1630-1642
58. Daaka, Y. (2002) Mitogenic action of LPA in prostate. Biochim. Biophys. Acta 1582, 265-269
59. Boucharaba, A., Guillet, B., Menaa, F., Hneino, M., van Wijnen, A. J., Clézardin, P., Philippe, C., Peyruchaud, O., and Oliver, P. (2009) Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol. Res. 18, 173-184
60. Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., and Tager, A. M. (2013) LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J27, 1830-1846
61. Takayanagi, H. (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304
62. Faccio, R., Takeshita, S., Zallone, A., Ross, F. P., and Teitelbaum, S. L. (2003) c-Fms and the v-3 integrin collaborate during osteoclast differentiation. J. Clin. Invest. 111, 749-758
63. Spencer, J. A., and Misra, R. P. (1999) Expression of the SRF gene occurs through a Ras/Sp/SRF-mediated-mechanism in response to serum growth signals. Oncogene 18, 7319-7327
64. Lin, M. E., Herr, D. R., and Chun, J. (2010) Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 91, 130-138
65. Peyruchaud, O., Leblanc, R., and David, M. (2013) Pleiotropic activity of lysophosphatidic acid in bone metastasis. Biochim. Biophys. Acta 1831, 99-104
66. Marx, U. C., Adermann, K., Bayer, P., Forssmann, W. G., and Rösch, P. (2000) Solution structures of human parathyroid hormone fragments hPTH(1-34) and hPTH(1-39) and bovine parathyroid hormone fragment bPTH(1-37). Biochem. Biophys. Res. Commun. 267, 213-220
67. Wysolmerski, J. J. (2012) Parathyroid hormone-related protein: an update. J. Clin. Endocrinol. Metab. 97, 2947-2956
68. Delmas, P. D., Vergnaud, P., Arlot, M. E., Pastoureau, P., Meunier, P. J., and Nilssen, M. H. (1995) The anabolic effect of human PTH(1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16, 603-610
69. Ferrari, S. L., Pierroz, D. D., Glatt, V., Goddard, D. S., Bianchi, E. N., Lin, F. T., Manen, D., and Bouxsein, M. L. (2005) Bone response to intermittent parathyroid hormone is altered in mice null forarrestin2. Endocrinology 146, 1854-1862
70. Onyia, J. E., Helvering, L. M., Gelbert, L., Wei, T., Huang, S., Chen, P., Dow, E. R., Maran, A., Zhang, M., Lotinun, S., Lin, X., Halladay, D. L., Miles, R. R., Kulkarni, N. H., Ambrose, E. M., Ma, Y. L., Frolik, C. A., Sato, M., Bryant, H. U., and Turner, R. T. (2005) Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J. Cell. Biochem. 95, 403-418
71. Coleman, R. (2011) The use of bisphosphonates in cancer treatment. Ann. N.Y. Acad. Sci. 1218, 3-14
72. Boucharaba, A., Serre, C. M., Guglielmi, J., Bordet, J. C., Clézardin, P., and Peyruchaud, O. (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. U.S.A. 103, 9643-9648
73. Rogers, M. J. (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9, 2643-2658
74. Gidley, J., Openshaw, S., Pring, E. T., Sale, S., and Mansell, J. P. (2006) Lysophosphatidic acid cooperates with 1-,25(OH)2D3 in stimulating human MG63 osteoblast maturation. Prostaglandins Other Lipid Mediat. 80, 46-61
75. Miyabe, Y., Miyabe, C., Iwai, Y., Takayasu, A., Fukuda, S., Yokoyama, W., Nagai, J., Jona, M., Tokuhara, Y., Ohkawa, R., Albers, H. M., Ovaa, H., Aoki, J., Chun, J., Yatomi, Y., Ueda, H., Miyasaka, M., Miyasaka, N., and Nanki, T. (2013) Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum. 65, 2037-2047